Meet Olof Breuer, MD, Clinical pharmacology lead
As a Clinical Pharmacologist at Karolinska University Hospital, Olof Breuer skillfully combines his medical expertise with a consultant role. He plays a crucial part at the hospital’s successful consulting business, delivering specialized advice in clinical pharmacology to various businesses.
When Olof Breuer was approached by PharmNovo in 2021 and asked whether he could help with clinical pharmacology consultancy services, the decision was easy.
“Most team members have a scientific background and are much driven by science and facts which, combined with an open atmosphere for discussion, fosters creativity. Working in such a team is a delight," says Olof Breuer.
Olof Breuer is appointed Clinical Pharmacology Lead, a strategic move that underscores PharmNovo's commitment to success. His extensive background in the pharmaceutical industry, with roles ranging from medical adviser to principal scientist, project manager, and clinical pharmacology director, equips Olof Breuer with a comprehensive understanding of the intricacies of drug development.
"I bring over 25 years of experience in drug development, of which 17 were spent in different roles within small and big pharma companies, for example, KaroBio and AstraZeneca. In addition, my current job as a senior consultant in the Clinical Trials Unit at the Clinical Pharmacology department within Karolinska University Hospital also brings hands-on clinical perspectives of pharmacokinetics, daily health care, and clinical trials."
An essential facet of Olof Breuer's skill set is his proficiency as a trained pharmacokinetics. By combining modelling and simulation techniques, Olof makes the design of studies and data analysis more efficient. This speeds up the research work and distils relevant data for decision-making, which is crucial when developing drugs.
"The fact that I am a "data analysis nerd" helps a lot in data mining so that potential problems can be identified early on and mitigated."
Olof's passion for addressing unmet medical needs, particularly in pain management, aligns perfectly with PharmNovo's mission to change the lives of people suffering from neuropathic pain.
"Research and development encompass problem-solving and creativity, which I consider important factors for job satisfaction. For me, such factors also add to the meaning of life."
Meet Olof Breuer, MD, Clinical pharmacology lead
As a Clinical Pharmacologist at Karolinska University Hospital, Olof Breuer skillfully combines his medical expertise with a consultant role. He plays a crucial part at the hospital’s successful consulting business, delivering specialized advice in clinical pharmacology to various businesses.
When Olof Breuer was approached by PharmNovo in 2021 and asked whether he could help with clinical pharmacology consultancy services, the decision was easy.
“Most team members have a scientific background and are much driven by science and facts which, combined with an open atmosphere for discussion, fosters creativity. Working in such a team is a delight," says Olof Breuer.
Olof Breuer is appointed Clinical Pharmacology Lead, a strategic move that underscores PharmNovo's commitment to success. His extensive background in the pharmaceutical industry, with roles ranging from medical adviser to principal scientist, project manager, and clinical pharmacology director, equips Olof Breuer with a comprehensive understanding of the intricacies of drug development.
"I bring over 25 years of experience in drug development, of which 17 were spent in different roles within small and big pharma companies, for example, KaroBio and AstraZeneca. In addition, my current job as a senior consultant in the Clinical Trials Unit at the Clinical Pharmacology department within Karolinska University Hospital also brings hands-on clinical perspectives of pharmacokinetics, daily health care, and clinical trials."
An essential facet of Olof Breuer's skill set is his proficiency as a trained pharmacokinetics. By combining modelling and simulation techniques, Olof makes the design of studies and data analysis more efficient. This speeds up the research work and distils relevant data for decision-making, which is crucial when developing drugs.
"The fact that I am a "data analysis nerd" helps a lot in data mining so that potential problems can be identified early on and mitigated."
Olof's passion for addressing unmet medical needs, particularly in pain management, aligns perfectly with PharmNovo's mission to change the lives of people suffering from neuropathic pain.
"Research and development encompass problem-solving and creativity, which I consider important factors for job satisfaction. For me, such factors also add to the meaning of life."
Latest news
View all
Positive final Phase I results
The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.
Read more
Meet Bengt von Mentzer, founder and Chief scientific advisor
Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.
Read more
NIDA funds studies
The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.
Read more
A new perspective in pain management and opioid withdrawal relief
We are proud to share an article in Dagens Industri about our groundbreaking work with PN6047. Our promising drug candidate not only has the potential to revolutionise pain relief but has also caught the attention of the National Institute on Drug Abuse (NIDA) for its role in opioid withdrawal treatment. Per von Mentzer, our CEO, states: "Our work with PN6047 could open new paths in pain relief. Particularly in neuropathic pain, our research could lead to new insights and novel treatment approaches in various clinical areas." PN6047, a selective DORA, offers a new perspective on both pain management and opioid withdrawal treatment. The results from the Phase I study show promising safety and tolerance, paving the way for further studies on its effects on opioid withdrawal syndrome.
Read more